FaceScan for Measuring Visual Acuity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new device called FaceScan to evaluate its accuracy in measuring vision compared to standard eye tests. It also seeks to develop a system that recognizes spoken letters by collecting voice recordings. Adults visiting the Ophthalmology Clinic who can provide consent are ideal candidates for this study. As an unphased trial, it offers participants the chance to contribute to innovative research that could improve future eye care technologies.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications.
What prior data suggests that the FaceScan device is safe for measuring visual acuity?
Research has shown that FaceScan, a digital tool for assessing vision, is designed to be safe and effective. The FDA classifies it as a system for testing vision, indicating its use in evaluating eyesight.
While specific safety details from studies aren't provided, ongoing research for accuracy and validation suggests general acceptance of FaceScan. The trial is in a "Not Applicable" phase, focusing on confirming the device's functionality rather than testing its safety on people, indicating that safety isn't a major concern at this stage.
Overall, FaceScan appears to be a promising tool for checking vision, with no specific reports of negative effects.12345Why are researchers excited about this trial?
Researchers are excited about the FaceScan technique for measuring visual acuity because it represents a new, digital approach to eye exams. Unlike traditional methods that rely on manual, chart-based tests, FaceScan uses advanced technology to deliver a digital visual acuity test. This method could potentially offer more precise and objective measurements, reducing human error. Plus, the convenience of a digital format may streamline the exam process, making it quicker and more accessible for both patients and healthcare providers.
What evidence suggests that the FaceScan device is effective for measuring visual acuity?
Research has shown that digital tools for assessing vision can be as accurate as traditional methods. Studies indicate that patients can even use these digital tools independently at home. In this trial, the FaceScan device aims to measure vision clarity by comparing its results to standard tests. Although specific data on FaceScan remains limited, the overall success of digital vision tests suggests it could perform effectively. Early results from similar technologies indicate reliable performance, making FaceScan a promising tool for vision assessment.13678
Who Is on the Research Team?
Antonio Forte, MD
Principal Investigator
Mayo Clinic
Are You a Good Fit for This Trial?
This trial is for adults over 18 years old who visit the Ophthalmology Clinic and can give consent. It's not specified who cannot participate, so it seems open to all adult patients needing visual acuity measurements.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline Assessment
Participants undergo a baseline ophthalmological examination including a digital visual acuity test with the FaceScan device
Follow-up
Participants are monitored for any immediate reactions or issues post-assessment
What Are the Treatments Tested in This Trial?
Interventions
- FaceScan
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor